The U.S. Food and Drug Administration has approved Vybrique, a new prescription treatment for erectile dysfunction that introduces a first of its kind oral film formulation of sildenafil. Announced on February 5, 2026 by IBSA USA, this approval marks a meaningful development in men’s sexual health, especially for those seeking discreet, convenient, and flexible treatment options.
Vybrique is indicated for adult men aged 18 years and older with erectile dysfunction and is expected to become commercially available in the United States in March 2026. With its dissolvable oral film design, multiple dosage strengths, and direct to home delivery model, Vybrique aims to address evolving patient needs while maintaining the established efficacy of sildenafil.
Erectile dysfunction affects an estimated 30 to 50 million men in the United States, making it one of the most common male sexual health conditions. While prevalence increases with age, erectile dysfunction is no longer limited to older adults. Recent research indicates a growing number of cases among men under 40, driven by a combination of physical, psychological, and lifestyle factors.
Conditions such as cardiovascular disease, diabetes, obesity, and hormonal imbalances can contribute to erectile dysfunction. Psychological factors including stress, anxiety, and depression are also strongly associated with the condition. As awareness grows, demand has increased for treatment options that are not only effective but also approachable and discreet.
Vybrique is a prescription medication that contains sildenafil, a phosphodiesterase type 5 inhibitor that has been widely used for decades in the treatment of erectile dysfunction. What differentiates Vybrique from existing sildenafil products is its delivery method.
Vybrique is the first and only FDA approved oral film formulation of sildenafil in the United States. The film dissolves directly on the tongue without the need for water or food. This design allows for more flexible use, particularly for patients who prefer not to swallow tablets or who want an option that fits into their daily routine with minimal disruption.
The oral film can be taken anywhere from 30 minutes to 4 hours before sexual activity and may be used with or without food.
Vybrique is developed using IBSA’s proprietary FilmTec technology. This formulation enables the active ingredient to dissolve quickly in the mouth, creating a convenient single dose administration.
Oral film technology has been increasingly explored in pharmaceuticals due to its potential benefits in patient adherence. For erectile dysfunction treatments, discretion and ease of use are particularly important, and the film format aligns with those preferences.
Vybrique is approved in four dosage strengths: 25 mg, 50 mg, 75 mg, and 100 mg. This range allows healthcare providers to tailor therapy based on individual patient needs, treatment response, and tolerability.
Flexible dosing is especially relevant for men who may be new to erectile dysfunction treatment or who have underlying medical conditions that require careful dose selection.
The FDA approval of Vybrique was supported by data from a randomized, double blind, placebo controlled, flexible dose clinical trial involving 475 adult men with erectile dysfunction.
Participants received Vybrique at doses ranging from 25 mg to 100 mg over a 12 week period. The study evaluated co primary efficacy endpoints related to improvements in sexual function, with assessments conducted at multiple time points including Week 4.
Results demonstrated that Vybrique provided statistically significant improvements in erectile function compared to placebo. Pharmacokinetic analyses showed that peak plasma concentrations of sildenafil were reached between 30 and 300 minutes under fasting conditions, with a median time of approximately 80 minutes.
These findings support both the efficacy and predictable absorption profile of the oral film formulation.
Despite increased public discussion around men’s sexual health, erectile dysfunction remains a sensitive topic for many patients. Discretion continues to be a major consideration when seeking treatment.
Vybrique’s dissolvable film format eliminates the need for water and allows for on the go use, which may help reduce treatment related anxiety and improve adherence. In addition, IBSA USA has announced that direct home delivery will be available in all states, offering an added layer of privacy and convenience.
According to IBSA USA leadership, Vybrique is designed to align with modern patient expectations by combining proven efficacy with a delivery system that fits seamlessly into everyday life.
Beyond physical causes, mental health plays a significant role in erectile dysfunction. Anxiety, depression, and chronic stress have all been shown to negatively impact sexual performance and confidence.
Healthcare professionals emphasize that addressing erectile dysfunction often requires a holistic approach that includes lifestyle modifications, mental health support, and appropriate medical treatment. The availability of discreet and easy to administer options like Vybrique may help reduce barriers to seeking care.
Vybrique contains sildenafil and carries the same safety considerations as other sildenafil based medications.
Vybrique can cause a sudden and unsafe drop in blood pressure if taken with nitrates or guanylate cyclase stimulators such as riociguat. Patients taking these medications should not use Vybrique.
Men should inform all healthcare providers that they are taking Vybrique, particularly in emergency situations involving heart conditions. Sexual activity itself places additional strain on the heart, and patients experiencing chest pain, dizziness, or nausea during sexual activity should seek immediate medical attention.
Serious side effects may include priapism, sudden vision loss due to non arteritic anterior ischemic optic neuropathy, and sudden hearing loss. Any erection lasting longer than four hours requires urgent medical care to prevent permanent damage.
Common side effects reported with sildenafil include headache, flushing, upset stomach, nasal congestion, dizziness, and visual disturbances.
Vybrique does not protect against sexually transmitted infections, including HIV.
Before starting Vybrique, patients should discuss their full medical history with a healthcare provider, especially if they have a history of heart disease, stroke, low or uncontrolled high blood pressure, liver or kidney disease, blood cell disorders, eye conditions such as retinitis pigmentosa, or prior episodes of prolonged erections.
Patients should also disclose all medications and supplements they are taking, including alpha blockers, antifungal medications, antibiotics, HIV protease inhibitors, and other erectile dysfunction treatments.
IBSA USA is the U.S. subsidiary of IBSA Institut Biochimique SA, a Swiss pharmaceutical company with a global presence in more than 90 countries. IBSA focuses on refining well known molecules through innovative drug delivery technologies across multiple therapeutic areas.
In 2025, IBSA marked the 40th anniversary of its acquisition by current President and CEO Arturo Licenziati, reflecting decades of growth driven by scientific innovation and patient focused development.
The approval of Vybrique expands the range of FDA approved erectile dysfunction treatments available in the United States. By offering a non tablet sildenafil option with multiple dose strengths and flexible administration, Vybrique may appeal to patients seeking convenience, discretion, and personalization in their care.
As erectile dysfunction continues to affect men across age groups, innovations in treatment delivery can play a critical role in improving quality of life and encouraging proactive management of sexual health.
Vybrique represents a notable advancement in erectile dysfunction treatment through its FDA approved oral film formulation of sildenafil. With proven clinical efficacy, a convenient administration method, and anticipated nationwide availability, Vybrique adds a new option for men managing erectile dysfunction.
Patients interested in Vybrique should consult a qualified healthcare provider to determine whether it is appropriate for their individual health needs.
IBSA USA press release, February 5, 2026
Safa A, Waked C. Erectile Dysfunction in Young Adults: A Narrative Review. Cureus. 2025
National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Erectile Dysfunction. 2024
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional with any questions regarding a medical condition or medication. Never disregard professional medical advice or delay seeking care because of information presented here.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.